life-sciences-tubes
isak55 / shutterstock.com
7 November 2016Big Pharma

IP Life Sciences Exchange: a preview

Session: Strategic steps to take in the wake of uncertain patent eligibility across biopharma

When: 12:45–13:15, November 15

This session kicks off with speakers representing the European Commission, and biotechnology companies Sotio and New England Biolabs. In this session, speakers will assess why it is important to have predictability and uniformity in the global biotech IP sector.

It will cover the expert group at the European Commission’s review of the biotech directive 98/44/EC, and look into strategies for coping with the erosion of patent eligibility in the US. This session will also look into problems of over-inclusiveness and indeterminacy in US jurisprudence on patentable subject matter.

Session: Personalised medicine and the importance of buy-in from all stakeholders

When: 17:30–18:00, November 15

In this session, presented by Jochen Maas, general manager, R&D Germany at Sanofi, personalised medicine will be explored from the R&D perspective. Aspects such as its effect on oncology, as well as its sociopolitical impact, will be explored.

This session will assess the need for business/legal certainty in order to invest in costly, risky, and lengthy R&D for clinical innovation. It will also explore the importance of support and involvement of all stakeholders.

Session: Injunctions in Indian pharmaceutical patent infringement actions

When: 09:00–09:30, November 16

This session will be led by Sandeep Rathod, from Mylan, who will explore the practicalities surrounding obtaining an interim injunction in a pharmaceutical patent suit.

It will assess the preference of patent owners to initiate suits and injunction requests before the High Court of Delhi as opposed to district and high courts. The session aims to create an understanding of the future increase in pharmaceutical patent infringement suits in India.

“The session aims to create an understanding of the future increase in pharmaceutical patent infringement suits in India.”

Session: Post Brexit, what does the unitary patent system and Unified Patent Court look like for life sciences?

When: 09:30–10:15, November 16

This interactive session will kick off with representatives from companies such as Polpharma, Merck and Esteve. It will cover issues including the extra layer of regulatory requirements in the pharma industry and cross-border injunctions.

This session will also look into the complications of enforcement, effective litigation management strategies, and freedom-to-operate considerations.